FDA Decision Watch: Regeneron And Roche's Autoimmune Drugs, Capricor's DMD Therapy In Spotlight

What happened

The FDA is expected to decide this month on Regeneron and Alnylam’s cemdisiran and Roche’s autoimmune treatments, though exact dates are undisclosed. Capricor’s Deramiocel decision was delayed by three months. Cemdisiran received Priority Review, and its Phase 3 trial showed better daily-functioning results than placebo after 24 weeks.

Confirmed

Global impact / market context

FDA decisions can determine whether these treatments may reach patients, shaping companies’ potential sales and development spending. Cemdisiran’s trial results provide evidence supporting its application, but approval is not assured; a delay for Deramiocel also extends uncertainty about when Capricor could receive a decision.

Analyst inference

The article identifies several pending decisions but gives no exact dates for the autoimmune treatments and no financial forecasts or share-price reaction. For investors, the near-term driver is regulatory news: approval could clarify commercial prospects, while a rejection or further delay could prolong uncertainty.

Analyst inference

What to watch

1. Watch for the FDA’s decision on cemdisiran and any disclosed timing; the article says the agency granted Priority Review and expects a decision this month. Confirmed
2. Check for FDA decisions on Roche’s autoimmune treatments, whose exact decision dates have not been disclosed in the supplied article. Confirmed
3. Follow updates on Capricor’s Deramiocel decision after its deadline was extended by three months; further timing changes could prolong uncertainty about potential sales. Analyst inference

Evidence

• stocktwits.com